| 3.26 -0.06 (-1.81%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.91 | 1-year : | 7.82 |
| Resists | First : | 4.21 | Second : | 6.69 |
| Pivot price | 1.94  |
|||
| Supports | First : | 0.18 | Second : | 0.15 |
| MAs | MA(5) : | 4.31 |
MA(20) : | 1.53 |
| MA(100) : | 1.59 |
MA(250) : | 2.48 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 51.8 |
D(3) : | 67.3 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 11.22 | Low : | 0.18 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GRI ] has closed below upper band by 35.1%. Bollinger Bands are 648.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.63 - 3.67 | 3.67 - 3.69 |
| Low: | 3.13 - 3.17 | 3.17 - 3.2 |
| Close: | 3.21 - 3.28 | 3.28 - 3.32 |
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Sat, 31 Jan 2026
Gri Bio Warns of Ongoing Internal Control Weaknesses That Could Threaten Financial Reporting Reliability and Investor Confidence - TipRanks
Fri, 30 Jan 2026
GRI Bio Expands At-The-Market Equity Offering Capacity - TipRanks
Thu, 29 Jan 2026
GRI Bio (GRI) expands at-the-market equity program to $60M capacity - Stock Titan
Wed, 28 Jan 2026
GRI Bio Reports Positive Study Results For Chronic Lung Disease, But Stock Slumps 20% — What Happened? - Stocktwits
Wed, 28 Jan 2026
GRI Bio reports positive gene expression data for IPF drug candidate - Investing.com
Wed, 28 Jan 2026
GRI Bio reports promising Phase 2a data in IPF - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 10.8 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 2,690 (K) |
| Shares Short P.Month | 142 (K) |
| EPS | 17.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -137.6 % |
| Return on Equity (ttm) | -397.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 0.18 |
| PEG Ratio | 0 |
| Price to Book value | 5.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|